#62 Page 72 and 73: KENNETH FORSYTHE e-mail: Kenneth_Fo Page 74 and 75: 1006 Judson Drive Mountain View, CA Page 76 and 77: THOMAS GEORGE 2 Ginkgo Court Up Page 78 and 79: KEVIN L
That it is somehow this like thing they shouldn't be doing, or it's less than
Before the company applied to the FDA for the drug to be approved for obesity, Knudsen and her colleagues 'developed a new methodology to show how [GLP-1] drugs exert their effect on the brain by working on the circumventricular organs and communicating further into the hypothalamus, among other effects.' This was designed to illustrate how GLP-1 worked in 'well- defined neurons in the hypothalamus, in the hindbrain, and in the reward centers.' Their rationale for developing the method was because 'It was very important to show that these medicines work on defined brain circuits and not ones that may be related to psychiatric or cardiovascular side effects, for example' (Nair
Because this is still an investigational compound, we frame the science honestly: what is genuinely studied, and what remains unknown
Substitutions on the adamantyl 3-hydroxyl group, such as carbamate or ester groups, have been shown to lead to diminished inhibitory potential
